{"id":"W2984708337","doi":"10.1007/s10637-019-00875-4","title":"A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study","year":2019,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen's University; CancerCare Manitoba; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University of Calgary; Centre Hospitalier de l’Université de Montréal; University Health Network","funders":"Terry Fox Research Institute; Canadian Cancer Society","keywords":"Glioblastoma; mTORC1; Cancer research; Medicine; Dual (grammatical number); Oncology; Internal medicine; Biology; Signal transduction; Philosophy; PI3K/AKT/mTOR pathway; Genetics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001071827,0.001485524,0.002631088,0.0004312108,0.0005235682,0.001110555,0.0008288453,0.001513347,0.002148],"category_scores_gemma":[0.0007881859,0.0006713527,0.002044366,0.0006955519,0.0008779391,0.0008026093,0.0003015912,0.003552263,0.0006903266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001621395,"about_ca_system_score_gemma":0.002100202,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004914296,"about_ca_topic_score_gemma":0.01584141,"domain_scores_codex":[0.9996434,0.0001223154,0.00001646498,0.00006996247,0.00003807197,0.0001098042],"domain_scores_gemma":[0.9994771,0.0000669345,0.00007863261,0.0000398848,0.00003877198,0.0002987463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6938848,0.05224302,0.02338271,0.001599081,0.005673653,0.001347951,0.0005143407,0.003369655,0.06235348,0.0005147239,0.01289785,0.1422187],"study_design_scores_gemma":[0.6285942,0.3153689,0.04056178,0.00007402461,0.002415702,0.0009508525,0.0001353761,0.001508089,0.003170648,0.000305083,0.006831047,0.00008430672],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894637,0.004335581,0.0004318964,0.0008304071,0.0002182142,0.001310664,0.001441607,0.00008673919,0.001881211],"genre_scores_gemma":[0.9872913,0.003955161,0.000925408,0.001525868,0.0002020781,0.001048465,0.003295773,0.00005098304,0.001704952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004914296,"threshold_uncertainty_score":0.01176411,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01016463032191543,"score_gpt":0.2622984673853777,"score_spread":0.2521338370634622,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}